Organogenesis Holdings Inc. (ORGO) 주식 분석

회사 개요

Organogenesis Holdings Inc. is a regenerative medicine enterprise focused on the development, manufacturing, and commercialization of products specifically for the advanced wound care, surgical, and sports medicine markets within the United States. The company operates within the broader Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on specialized therapeutic solutions rather than mass-market pharmaceuticals. As of the latest data, the company maintains a market capitalization of $307.45M and generates an annual revenue of $564.17M while employing 854 individuals. These financial dimensions indicate that Organogenesis holds a mid-cap position in the specialty drug manufacturing landscape, reflecting a substantial operational footprint capable of supporting significant R&D and commercialization efforts without yet reaching the scale of large-cap pharmaceutical peers.

재무 건전성

The company reported a trailing twelve-month revenue of $564.17M and a net income of $20.02M, resulting in an EBITDA of $74.98M. The substantial gap between the $564.17M revenue and the $20.02M net income reveals a distinct cost structure where operating expenses, including cost of goods sold and administrative costs, consume a significant portion of gross earnings before reaching the bottom line. However, the free cash flow stands at -$50,102,376, indicating that despite generating accounting profits, the company is currently consuming cash, likely due to heavy capital expenditures required for manufacturing scale-up or research and development activities. This negative cash flow suggests limited immediate financial flexibility for aggressive share buybacks or dividend payments, necessitating reliance on existing cash reserves or external financing. The gross margin is reported at 75.6%, which indicates a highly efficient production model where the cost of goods sold is less than a quarter of revenue. The operating margin sits at 28.9%, showing that after covering operating expenses, the company retains a robust portion of revenue from core operations. The profit margin of 6.6% further contextualizes the final profitability available to shareholders after all expenses, taxes, and interest are accounted for. Regarding balance sheet strength, the company holds $95.92M in cash against $82.14M in debt, supported by a debt-to-equity ratio of 18.93 and a current ratio of 3.62. The current ratio of 3.62 signifies a very strong short-term liquidity position, as the company possesses more than three times the current assets necessary to cover its current liabilities. Furthermore, the return on equity is 9.0% and the return on assets is 6.4%, metrics that reveal management's effectiveness in generating returns on the capital invested by shareholders and the total asset base respectively.

밸류에이션 평가

The valuation of Organogenesis is characterized by a trailing P/E ratio of 15.93 and a forward P/E of 8.24. The significant difference between the trailing P/E of 15.93 and the forward P/E of 8.24 implies that the market expects earnings to expand rapidly in the future, thereby reducing the multiple required to value the company's stock. The price-to-book ratio is 1.01, which indicates that the market values the company at approximately its net asset book value, suggesting no significant premium or discount relative to its tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 0.54 and the EV/EBITDA of 5.70 suggest that the stock is priced conservatively relative to its sales and operating earnings, which is common for companies in the early stages of scaling or those reinvesting heavily in growth. The 52-week price range spans from a low of $2.21 to a high of $7.08, providing a clear context for current trading levels relative to recent volatility. The beta value of 1.48 indicates that the stock exhibits higher price volatility relative to the broader market, moving approximately 48% more than the market index during periods of fluctuation. These metrics collectively present a valuation profile that balances conservative asset backing with expectations of future earnings expansion and inherent market volatility.

Growth & Income

Organogenesis demonstrates exceptional growth dynamics with a revenue growth rate of 78.1% year-over-year and an earnings growth rate of 555.2% year-over-year. The earnings growth rate of 555.2% is significantly faster than the revenue growth rate of 78.1%, which implies that the company is experiencing substantial leverage from operating efficiencies, pricing power, or a rapid expansion in high-margin product sales. The company does not currently pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that all net income is retained within the business. This reinvestment strategy allows the company to fund its negative free cash flow of -$50,102,376 and pursue growth initiatives such as new product launches or market expansion rather than distributing cash to shareholders. Consequently, the overall growth and income profile is defined by aggressive top-line expansion and earnings scaling rather than current income generation through dividends, positioning the equity as a pure growth play within the healthcare sector.